<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01018784</url>
  </required_header>
  <id_info>
    <org_study_id>MORAB-009-J081-102</org_study_id>
    <nct_id>NCT01018784</nct_id>
  </id_info>
  <brief_title>A Study of MORAb-009 in Patients With Solid Tumor</brief_title>
  <official_title>A Phase 1 Study of MORAb-009 in Patients With Solid Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <brief_summary>
    <textblock>
      MORAb-009 is intravenously administered to patients with solid tumor once a week for 4 weeks
      as 1 cycle in order to investigate dose-limiting toxicity and estimate maximum tolerated
      dose.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To investigate dose-limiting toxicity and estimate maximum tolerated dose.</measure>
    <time_frame>4 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The best overall response rate in the RECIST evaluation and the preliminary evaluation calculating the frequency of Completed response and Partial Response.</measure>
    <time_frame>During Study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Cancer</condition>
  <condition>Mesothelin-positive</condition>
  <arm_group>
    <arm_group_label>MORAb-009</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MORAb-009</intervention_name>
    <description>MORAb-009 is intravenously administered to patients with solid tumor once a week for 4 weeks as 1 cycle.</description>
    <arm_group_label>MORAb-009</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria;

          1. Japanese male and female patients aged from 20 to less than 80 years at obtaining
             informed consent

          2. Patient with histologically or cytologically diagnosed solid tumor

          3. Patient who is mesothelin-positive confirmed by immunohistochemistry (IHC) (except for
             pancreatic cancer and mesothelioma that mesothelin-positive is frequently reported)

          4. Patient with solid tumor who is non responder to or resistant to standard therapy and
             has no other appropriate treatment

          5. Performance Status (PS) is 0 to 1 by Eastern Cooperative Oncology Group ECOG criteria

        Exclusion criteria

          1. Brain metastasis presenting clinical symptoms or requiring medical treatment

          2. Serious and systemic infection requiring medical treatment

          3. History of hypersensitivity to protein formulations including monoclonal antibody

          4. With active multiple carcinoma (except for carcinoma in situ and intramucosal
             carcinoma)

          5. With celomic fluid (pleural effusion or ascites) uncontrolled by drainage, or with a
             large volume of celomic fluid
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chifumi Kitamura</last_name>
    <role>Study Director</role>
    <affiliation>Morphotek Clinical Development Section, JAC PCU</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Sayama-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2009</study_first_submitted>
  <study_first_submitted_qc>November 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2009</study_first_posted>
  <last_update_submitted>January 19, 2016</last_update_submitted>
  <last_update_submitted_qc>January 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Mesothelin-positive</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

